What is Day Zero Diagnostics?
Day Zero Diagnostics, Inc., based in Boston, is at the forefront of infectious disease diagnostics, leveraging whole-genome sequencing and machine learning. The company's innovative approach aims to combat antibiotic resistance by rapidly identifying pathogens and their resistance profiles, bypassing traditional culture methods. This technology also facilitates big data analysis for managing healthcare-associated infection outbreaks. Founded in 2016 by experts from Harvard University and Massachusetts General Hospital, Day Zero Diagnostics has garnered recognition from numerous leading health and innovation organizations.
How much funding has Day Zero Diagnostics raised?
Day Zero Diagnostics has raised a total of $55.3M across 6 funding rounds:
Angel/Seed
$3M
Series A
$8.6M
Corporate Investment
$6.2M
Debt
$467K
Unspecified
$21M
Other Financing Round
$16M
Angel/Seed (2017): $3M with participation from Golden Seeds and Sands Capital
Series A (2019): $8.6M, investors not publicly disclosed
Corporate Investment (2020): $6.2M supported by Carb-X
Debt (2021): $467K featuring PPP
Unspecified (2022): $21M backed by Golden Seeds, Sands Capital, Triventures, Panacea Ventures, BD, and Hongkou Capital
Other Financing Round (2023): $16M, investors not publicly disclosed
Key Investors in Day Zero Diagnostics
Golden Seeds
Golden Seeds is a venture capital firm specializing in start-up, early stage, and growth capital investments, with a significant presence across multiple US cities.
Sands Capital
Sands Capital Management, established in 1992, manages equity mutual funds and invests in public equity markets, headquartered in Arlington, Virginia.
Triventures
Triventures is a global venture capital fund focused on early-stage companies in healthcare and other industries, emphasizing bio-convergence and data-driven technologies.
What's next for Day Zero Diagnostics?
The substantial enterprise-level capital infusion positions Day Zero Diagnostics for significant scaling and further development of its groundbreaking diagnostic platform. This strategic backing is expected to accelerate the company's mission to transform infectious disease diagnosis and treatment globally, potentially leading to broader adoption of its technology in clinical settings and public health initiatives. The company's focus on rapid, culture-independent identification of infections and resistance mechanisms is critical in addressing the escalating challenge of antimicrobial resistance.
See full Day Zero Diagnostics company page
